Danielle Brill
Stock Analyst at Truist Securities
(3.96)
# 610
Out of 5,090 analysts
92
Total ratings
48.75%
Success rate
12.61%
Average return
Main Sectors:
Stocks Rated by Danielle Brill
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PVLA Palvella Therapeutics | Maintains: Buy | $80 → $105 | $101.43 | +3.52% | 3 | Nov 10, 2025 | |
| IRON Disc Medicine | Maintains: Buy | $86 → $114 | $92.78 | +22.88% | 7 | Nov 10, 2025 | |
| NBIX Neurocrine Biosciences | Reiterates: Buy | $165 → $172 | $155.31 | +10.75% | 7 | Oct 30, 2025 | |
| BBIO BridgeBio Pharma | Reiterates: Buy | $66 → $80 | $73.30 | +9.14% | 2 | Oct 30, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $459 → $535 | $459.12 | +16.53% | 2 | Oct 17, 2025 | |
| IMVT Immunovant | Initiates: Hold | $16 | $22.66 | -29.39% | 5 | Oct 14, 2025 | |
| UPB Upstream Bio | Initiates: Buy | $47 | $27.95 | +68.16% | 1 | Oct 14, 2025 | |
| DNTH Dianthus Therapeutics | Initiates: Buy | $56 | $44.07 | +27.07% | 1 | Oct 14, 2025 | |
| VRTX Vertex Pharmaceuticals | Initiates: Market Perform | n/a | $454.71 | - | 3 | Sep 3, 2025 | |
| HRMY Harmony Biosciences Holdings | Initiates: Buy | $48 | $39.55 | +21.37% | 8 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $64 | $20.33 | +214.88% | 2 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $29.85 | +0.50% | 1 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $20.36 | +17.88% | 1 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Strong Buy | $20 → $52 | $21.09 | +146.56% | 6 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $20.10 | - | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $79 | $53.12 | +48.72% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $18 | $13.05 | +37.93% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $150 | $22.30 | +572.80% | 3 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $182.14 | - | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Strong Buy | $605 | $899.90 | -32.77% | 7 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $27.38 | - | 5 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $50 | $44.66 | +11.96% | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $51 | $27.63 | +84.58% | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $180 → $100 | $9.13 | +995.29% | 5 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $77.11 | - | 9 | Sep 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $8.30 | - | 5 | Jun 27, 2023 |
Palvella Therapeutics
Nov 10, 2025
Maintains: Buy
Price Target: $80 → $105
Current: $101.43
Upside: +3.52%
Disc Medicine
Nov 10, 2025
Maintains: Buy
Price Target: $86 → $114
Current: $92.78
Upside: +22.88%
Neurocrine Biosciences
Oct 30, 2025
Reiterates: Buy
Price Target: $165 → $172
Current: $155.31
Upside: +10.75%
BridgeBio Pharma
Oct 30, 2025
Reiterates: Buy
Price Target: $66 → $80
Current: $73.30
Upside: +9.14%
Alnylam Pharmaceuticals
Oct 17, 2025
Maintains: Buy
Price Target: $459 → $535
Current: $459.12
Upside: +16.53%
Immunovant
Oct 14, 2025
Initiates: Hold
Price Target: $16
Current: $22.66
Upside: -29.39%
Upstream Bio
Oct 14, 2025
Initiates: Buy
Price Target: $47
Current: $27.95
Upside: +68.16%
Dianthus Therapeutics
Oct 14, 2025
Initiates: Buy
Price Target: $56
Current: $44.07
Upside: +27.07%
Vertex Pharmaceuticals
Sep 3, 2025
Initiates: Market Perform
Price Target: n/a
Current: $454.71
Upside: -
Harmony Biosciences Holdings
Jul 21, 2025
Initiates: Buy
Price Target: $48
Current: $39.55
Upside: +21.37%
Jul 21, 2025
Initiates: Buy
Price Target: $64
Current: $20.33
Upside: +214.88%
Jul 21, 2025
Initiates: Buy
Price Target: $30
Current: $29.85
Upside: +0.50%
Jul 21, 2025
Initiates: Buy
Price Target: $24
Current: $20.36
Upside: +17.88%
Dec 10, 2024
Upgrades: Strong Buy
Price Target: $20 → $52
Current: $21.09
Upside: +146.56%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $20.10
Upside: -
Oct 10, 2024
Reinstates: Outperform
Price Target: $79
Current: $53.12
Upside: +48.72%
Oct 10, 2024
Reinstates: Outperform
Price Target: $18
Current: $13.05
Upside: +37.93%
Oct 10, 2024
Reinstates: Outperform
Price Target: $150
Current: $22.30
Upside: +572.80%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $182.14
Upside: -
Oct 10, 2024
Reinstates: Strong Buy
Price Target: $605
Current: $899.90
Upside: -32.77%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $27.38
Upside: -
Oct 10, 2024
Reinstates: Outperform
Price Target: $50
Current: $44.66
Upside: +11.96%
Oct 10, 2024
Reinstates: Outperform
Price Target: $51
Current: $27.63
Upside: +84.58%
Nov 14, 2023
Maintains: Outperform
Price Target: $180 → $100
Current: $9.13
Upside: +995.29%
Sep 18, 2023
Downgrades: Underperform
Price Target: n/a
Current: $77.11
Upside: -
Jun 27, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $8.30
Upside: -